Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?

Bristol Myers' Sotyktu delivered positive two-year data from the POETYK PsA-2 study, with the oral TYK2 inhibitor maintaining durable efficacy and consistent safety through week 104 in psoriatic arthritis patients. The drug generated $156 million in revenue during the first half of 2026, up 24% year-over-year, according to Zacks Investment Research.

Sotyktu (deucravacitinib) is approved for plaque psoriasis and psoriatic arthritis, with pipeline expansion targeting lupus and Sjögren's disease indications. The long-term data supports the drug's differentiation in an increasingly competitive immunology market, where BMY faces pressure from established players including AMGN's Otezla and biosimilar competition across its portfolio.

The 24% revenue growth reflects strong uptake trajectory, though Sotyktu remains a relatively small contributor to BMY's overall sales base. The company is banking on oral TYK2 inhibition as a platform technology, with the autoimmune franchise critical to offsetting patent losses in oncology, including Revlimid (acquired via the $74 billion CELGR acquisition).